Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

The U.S. Food and Drug Administration (FDA) on Thursday announced an expedited plan to implement artificial intelligence (AI) ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 08, 2025 ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Shares of Biogen Inc. BIIB slipped 4.09% to $116.82 Tuesday, on what proved to be an all-around grim trading session for the ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Discover key insights from Biogen's Q1 2025 earnings call, highlighting LEQEMBI's growth, product launches, and a strong pipeline driving ...